Presentation is loading. Please wait.

Presentation is loading. Please wait.

Using Whole Genome Amplification (WGA) of Low-Volume Biopsies to Assess the Prognostic Role of EGFR, KRAS, p53, and CMET Mutations in Advanced-Stage Non-

Published byAron Bradley Modified over 6 years ago

Similar presentations

Presentation on theme: "Using Whole Genome Amplification (WGA) of Low-Volume Biopsies to Assess the Prognostic Role of EGFR, KRAS, p53, and CMET Mutations in Advanced-Stage Non-"— Presentation transcript:

1 Using Whole Genome Amplification (WGA) of Low-Volume Biopsies to Assess the Prognostic Role of EGFR, KRAS, p53, and CMET Mutations in Advanced-Stage Non- small Cell Lung Cancer (NSCLC)  Elaine H. Lim, MD, PhD, Shen-Li Zhang, MD, Jia-Liang Li, PhD, Wee-See Yap, MD, Tse-Chiang Howe, MD, Bien-Peng Tan, MD, Yong- Shyan Lee, MD, Daniel Wong, MD, Kay-Leong Khoo, MD, Kar-Yin Seto, MD, Lenny Tan, MD, Thirugananam Agasthian, MD, Heng- Nung Koong, MD, John Tam, MD, Christie Tan, MD, Michael Caleb, MD, Alex Chang, MD, Alan Ng, MD, Patrick Tan, MD, PhD  Journal of Thoracic Oncology  Volume 4, Issue 1, Pages (January 2009) DOI: /JTO.0b013e e28 Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Detection of deoxyribonucleic acid (DNA) mutations in unamplified and whole genome amplification (WGA)-amplified genomic DNA (gDNA) extracted from surgically-resected lung tumors. Left column, Sequence chromatograms of wildtype tumors using unamplified gDNA. Middle column, Sequence chromatograms of mutation-bearing tumors using unamplified gDNA. Right column, Sequence chromatograms of mutation-bearing tumors, same as in the middle column, but using WGA-amplified gDNA. Identity numbers of the mutation-bearing tumors are listed on the right. A, epidermal growth factor receptor (EGFR) exon 19: the start of the heterozygous in-frame deletion (delE746-A750) is indicated by the arrows. B, Kras exon 2: the heterozygous missense mutation (G12C) is indicated by the arrows. C, p53 exon 5: the start of the heterozygous in-frame deletion (delR158-Y163) is indicated by the arrows. Journal of Thoracic Oncology 2009 4, 12-21DOI: ( /JTO.0b013e e28) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Detection of deoxyribonucleic acid (DNA) mutations in unamplified and whole genome amplification (WGA)-amplified genomic DNA (gDNA) extracted from low-volume lung biopsies. Left column, Sequence chromatograms of wildtype tumors using unamplified gDNA. Middle column, Sequence chromatograms of mutation-bearing tumors using unamplified gDNA. Right column, Sequence chromatograms of mutation-bearing tumors, same as in the middle column, but using WGA-amplified gDNA. Identity numbers of the mutation-bearing tumors are listed on the right. A, p53 exon 5: the heterozygous missense mutation (R158L) is indicated by the arrows. B, p53 exon 7: the heterozygous missense mutation (Y236stop) is indicated by the arrows. Journal of Thoracic Oncology 2009 4, 12-21DOI: ( /JTO.0b013e e28) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 A, Overall survival of 88 non-small cell lung cancer (NSCLC) patients (survival time in days). The dotted lines indicate 95% confidence intervals. B, Survival curves of patients with and without KRAS mutations (survival time in days). C, Survival curves of patients with and without epidermal growth factor receptor (EGFR) mutations (survival time in days). Journal of Thoracic Oncology 2009 4, 12-21DOI: ( /JTO.0b013e e28) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Using Whole Genome Amplification (WGA) of Low-Volume Biopsies to Assess the Prognostic Role of EGFR, KRAS, p53, and CMET Mutations in Advanced-Stage Non-"

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Yes, Patient #1 Yes, Patient #3 EGFR sequencing chromatograms

Yes, Patient #1 Yes, Patient #3 EGFR sequencing chromatograms
EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients  Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.

EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients  Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.
T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,
An Alternative Method for Screening EGFR Mutation Using RFLP in Non-small Cell Lung Cancer Patients  Ichiro Kawada, MD, Kenzo Soejima, MD, PhD, Hideo.

An Alternative Method for Screening EGFR Mutation Using RFLP in Non-small Cell Lung Cancer Patients  Ichiro Kawada, MD, Kenzo Soejima, MD, PhD, Hideo.
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.

EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.
Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity 

Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity 
EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients  Natalia Sutiman, BSc, Shao.

EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients  Natalia Sutiman, BSc, Shao.
Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.
The CTC-Chip: An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients  Lecia V. Sequist, MD, MPH, Sunitha Nagrath, PhD, Mehmet.

The CTC-Chip: An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients  Lecia V. Sequist, MD, MPH, Sunitha Nagrath, PhD, Mehmet.
Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer  Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.

Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer  Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.
Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR  Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR  Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

Similar presentations

Ads by Google